Inventor · disambiguated record
David Scott Carter
Also filed as: CARTER DAVID · CARTER DAVID S · CARTER DAVID SCOTT
17 granted patents·22 pending applications·141 citations·filing 1975–2024
93Inventor score
Files withROCHE PALO ALTO LLC19CURASEN THERAPEUTICS INC9ANACOR PHARMACEUTICALS INC5BROKA CHRIS ALLEN2FISONS LTD2
Top patents by PatentIndex Score
39 records- 0195US7858632B2Diaminopyrimidines as P2X3 and P2X2/3 antagonistsROCHE PALO ALTO LLC·Filed 2005·Granted Dec 28, 2010·28 cites·30 claims
- 0293US8008313B2Methods of using diaminopyrimidine P2X3 and P2X2/3 receptor modulators for treatment of respiratory and gastrointestinal diseasesROCHE PALO ALTO LLC·Filed 2006·Granted Aug 30, 2011·20 cites·13 claims
- 0392US2025066309A1Diaminopyrimidines as p2x3 and p2x2/3 antagonistsROCHE PALO ALTO LLC·Filed 2024·Application pending·0 cites
- 0490US10947196B2Beta adrenergic agonist and methods of using the sameCURASEN THERAPEUTICS INC·Filed 2020·Granted Mar 16, 2021·2 cites·6 claims
- 0590US8846705B2Diaminopyrimidines as P2X3 and P2X2/3 antagonistsBROKA CHRIS ALLEN·Filed 2010·Granted Sep 30, 2014·11 cites·24 claims
- 0689US2025025462A1Methods of using diaminopyrimidine p2x3 and p2x2/3 receptor modulators for treatment of respiratory and gastrointestinal diseasesROCHE PALO ALTO LLC·Filed 2024·Application pending·0 cites
- 0788US8524725B2Methods of using diaminopyrimidine as P2X3 and P2X⅔ receptor modulators for treatment of respiratory and gastrointestinal diseasesBROKA CHRIS ALLEN·Filed 2011·Granted Sep 3, 2013·9 cites·13 claims
- 0887US2024158356A1Diaminopyrimidines as p2x3 and p2x2/3 antagonistsROCHE PALO ALTO LLC·Filed 2023·Application pending·0 cites
- 0987US2025304603A1Oxaborole esters and uses thereofANACOR PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1083US11040944B2Beta adrenergic agonist and methods of using the sameCURASEN THERAPEUTICS INC·Filed 2020·Granted Jun 22, 2021·1 cites·20 claims
- 1182US8273773B2Heterocyclic antiviral compoundsBRAMELD KENNETH ALBERT·Filed 2009·Granted Sep 25, 2012·11 cites·33 claims
- 1282US2023100975A1Diaminopyrimidines as p2x3 and p2x2/3 antagonistsROCHE PALO ALTO LLC·Filed 2022·Application pending·0 cites
- 1381US5739336A1,3,8-triaza- and 3,8-diaza-1-oxaspiro 4,5! decane derivativesSYNTEX INC·Filed 1996·Granted Apr 14, 1998·32 cites·17 claims
- 1481US2023132298A1Oxaborole esters and uses thereofANACOR PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1577US9556127B2Diaminopyrimidines as P2X3 and P2X2/3 antagonistsROCHE PALO ALTO LLC·Filed 2014·Granted Jan 31, 2017·1 cites·9 claims
- 1676US10562921B2Oxaborole esters and uses thereofANACOR PHARMACEUTICALS INC·Filed 2017·Granted Feb 18, 2020·1 cites·22 claims
- 1776US4133889A2(5-Tetrazolyl)chromonesFISONS LTD·Filed 1976·Granted Jan 9, 1979·11 cites·6 claims
- 1875US7754721B2Arylpiperazine derivatives and uses thereofROCHE PALO ALTO LLC·Filed 2007·Granted Jul 13, 2010·2 cites·19 claims
- 1975US2021009531A1Diaminopyrimidines as p2x3 and p2x2/3 antagonistsROCHE PALO ALTO LLC·Filed 2020·Application pending·0 cites
- 2074US10882872B2Oxaborole esters and uses thereofANACOR PHARMACEUTICALS INC·Filed 2019·Granted Jan 5, 2021·0 cites·13 claims
- 2174US2021008071A1Methods of using diaminopyrimidine p2x3 and p2x2/3 receptor modulators for treatment of respiratory and gastrointestinal diseasesROCHE PALO ALTO LLC·Filed 2020·Application pending·0 cites
- 2273US2020115347A1Diaminopyrimidines as p2x3 and p2x2/3 antagonistsROCHE PALO ALTO LLC·Filed 2019·Application pending·0 cites
- 2372US2021371380A1Beta adrenergic agonist and methods of using the sameCURASEN THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2472US2019270713A1Diaminopyrimidines as p2x3 and p2x2/3 antagonistsROCHE PALO ALTO LLC·Filed 2019·Application pending·0 cites
- 2571US11578087B2Oxaborole esters and uses thereofANACOR PHARMACEUTICALS INC·Filed 2020·Granted Feb 14, 2023·0 cites·11 claims
- 2670US12448352B2Beta adrenergic agonist and methods of using the sameCURASEN THERAPEUTICS INC·Filed 2020·Granted Oct 21, 2025·0 cites·20 claims
- 2770US2019016688A1Diaminopyrimidines as p2x3 and p2x2/3 antagonistsROCHE PALO ALTO LLC·Filed 2018·Application pending·0 cites
- 2868US2018141919A1Diaminopyrimidines as p2x3 and p2x2/3 antagonistsROCHE PALO ALTO LLC·Filed 2017·Application pending·0 cites
- 2966US2018311240A1Methods of using diaminopyrimidine p2x3 and p2x2/3 receptor modulators for treatment of respiratory and gastrointestinal diseasesROCHE PALO ALTO LLC·Filed 2018·Application pending·0 cites
- 3065US2017096404A1Diaminopyrimidines as p2x3 and p2x2/3 antagonistsROCHE PALO ALTO LLC·Filed 2016·Application pending·0 cites
- 3162US2013225570A1Methods of using diaminopyrimidine p2x3 and p2x2/3 receptor modulators for treatment of respiratory and gastrointestinal diseasesROCHE PALO ALTO LLC·Filed 2013·Application pending·0 cites
- 3262US2025188060A1Alpha1a-adrenergic receptor agonists and methods of useCURASEN THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3360US2016271131A1Methods of using diaminopyrimidine p2x3 and p2x2/3 receptor modulators for treatment of respiratory and gastrointestinal diseasesROCHE PALO ALTO LLC·Filed 2016·Application pending·0 cites
- 3457US4006245AChemical compoundsFISONS LTD·Filed 1975·Granted Feb 1, 1977·12 cites·1 claims
- 3556US2024352002A1Beta adrenergic agonist and methods of using the sameCURASEN THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3656US2023312524A1Alpha1a-adrenergic receptor agonists and methods of useCURASEN THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3754US2023219892A1Forms and compositions of a beta adrenergic agonistCURASEN THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3853US7998963B2Arylpiperazine derivatives and uses thereofROCHE PALO ALTO LLC·Filed 2009·Granted Aug 16, 2011·0 cites·24 claims
- 3951US2022315534A1Beta adrenergic agonist and methods of using the sameCURASEN THERAPEUTICS INC·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when David Scott Carter files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →